Samsung Biologics, the contract development and manufacturing arm of the South Korean conglomerate, has tabled a $1.46 billion (£1.1 billion) bid for PolyPeptide Group, a European manufacturer of peptide-based drugs. The offer, announced on Monday, represents a significant premium to PolyPeptide's recent trading price and underscores the intensifying race among global pharma outsourcers to secure manufacturing capacity.
PolyPeptide, headquartered in Switzerland with facilities across Europe, specialises in producing complex peptide chains used in treatments for diabetes, cancer, and rare metabolic disorders. The company has been a key supplier to several UK-based biotech firms and NHS supply chains, particularly for generic versions of blockbuster drugs such as liraglutide and semaglutide.
News of the bid comes as the FTSE 100 slipped 0.3% to 8,214 points in mid-afternoon trading, with the healthcare sector under mild pressure. Shares in UK-listed contract research organisations such as Ergomed and Clinigen were broadly flat, though analysts noted that the deal could prompt further M&A in the sector. 'We are seeing a strategic pivot by Asian CDMOs to secure European production hubs,' said Dr. Helen Marr, healthcare analyst at London-based Shore Capital. 'For UK investors, this means the valuation floor for specialist pharma manufacturers is rising.'
The bid also raises questions about supply chain resilience for UK drugmakers. PolyPeptide's Belgian and Swedish sites supply active ingredients used in NHS hospital tenders for oncology and hormone therapies. If the acquisition proceeds, UK regulators may seek assurances over continued supply and pricing, particularly given the current government focus on domestic medicine security following the 2023-24 shortages.
For UK pension holders, the deal highlights the growing exposure of global equity portfolios to healthcare outsourcing. Many UK defined-contribution schemes hold positions in European small-cap healthcare funds that include PolyPeptide. A successful bid at a premium could deliver short-term gains, though analysts caution that sector consolidation often leads to higher drug production costs over time.
PolyPeptide's board has confirmed it is reviewing the offer and has advised shareholders to take no action for now. A formal recommendation is expected within the coming weeks, with the deal likely to face scrutiny from EU and UK competition authorities given the strategic nature of peptide manufacturing.